Goldman Sachs Maintains Buy on Denali Therapeutics, Raises Price Target to $40
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst Salveen Richter maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $35 to $40.
Goldman Sachs analyst Salveen Richter maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $35 to $40.